Amplia Therapeutics Ltd (ATX)
20mins delayed
Movement
1 Year Return
Amplia Therapeutics Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $8.31 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
ATX Statistics
13 July
1,858 / 2,231
ASX Size Rank
1yr Return
vs Sector (1yr)
+27.00%
vs ASX 200 (1yr)
+57.62%
$8.31 million
Market Cap
Share Issue
66.46 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
13 July
N/A
PE Ratio
EPS ($)
-0.046
Earnings Yield
-36.80%
NTA ($)
0.01
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Amplia Therapeutics Limited (ATX, formerly Innate Immunotherapeutics Limited) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
Former Names
Innate Immunotherapeutics Limited (IIL), 07/09/2018
Upcoming Calendar
| 14 Jul 2020 | Issued Shares |
| 23 Jul 2020 | Report (Annual) |
| 27 Nov 2020 | Report (Interim) |
| 28 May 2021 | Report (Prelim) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
ATX is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr Andrew John Cooke | Company Secretary | Oct 2013 |
|
| Dr John Lambert | Chief Executive Officer, Managing Director | Jun 2019 |
|
| Dr Robert Peach | Non-Executive Director | Sep 2015 |
|
| Dr Warwick Bonner Tong | Non-Executive Director, Non-Executive Chairman | May 2018 |
|
| Dr Christopher John Burns | Non-Executive Director | May 2018 |
|
Director Transactions
ATX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 17/09/19 | Robert Peach | Transfer | 56,000 | $0.080 | $4,480 | Off-market transfer. |
| 17/09/19 | Robert Peach | Issued | 500,000 | $0.080 | $40,000 | Placement. |
| 17/09/19 | Robert Peach | Issued | 1,000,000 | $0.100 | $100,000 | Placement. |
| 17/09/19 | Christian Behrenbruch | Issued | 250,000 | $0.100 | $25,000 | Placement. |
| 17/09/19 | Christian Behrenbruch | Issued | 125,000 | $0.080 | $10,000 | Placement. |
| 17/09/19 | Warwick Tong | Issued | 250,000 | $0.100 | $25,000 | Placement. |
| 17/09/19 | Warwick Tong | Issued | 125,000 | $0.080 | $10,000 | Placement. |
| 20/08/19 | Simon Wilkinson | Expiry | 175,000 | $0.077 | $13,475 | Options expired. |
| 02/08/19 | Andrew Cooke | Issued | 125 | $10.000 | $1,250 | Rights issue. |
| 02/08/19 | Andrew Cooke | Issued | 63 | $0.095 | $6 | Rights issue. |
| 02/08/19 | Warwick Tong | Issued | 40,000 | $0.098 | $3,920 | Rights issue. |
| 02/08/19 | Warwick Tong | Issued | 80,000 | $0.100 | $8,000 | Rights issue. |
| 02/08/19 | Christopher Burns | Issued | 60,000 | $0.100 | $6,000 | Rights issue. |
| 02/08/19 | Christopher Burns | Issued | 30,000 | $0.098 | $2,940 | Rights issue. |
| 06/11/18 | Andrew Cooke | Buy | +120 | $0.308 | $37 | Off-market trade. |
| 05/11/18 | Simon Wilkinson | Expiry | 100,000 | $0.270 | $27,000 | Options expired. |
| 31/08/18 | Andrew Cooke | Issued | 480,000 | $0.370 | $177,600 | Issue of options. |
| 31/08/18 | Simon Wilkinson | Issued | 1,370,000 | $0.370 | $506,900 | Issue of securities. |
| 31/08/18 | Simon Wilkinson | Expiry | 175,000 | $0.370 | $64,750 | Options expired. |
| 31/08/18 | Robert Peach | Expiry | 100,000 | $0.370 | $37,000 | Options expired. |
| 31/08/18 | Robert Peach | Issued | 480,000 | $0.370 | $177,600 | Issue of options. |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 1,767 | 656 | 192 | 225 | 44 | 2,884 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 6,357,072 | 14.25% |
| CTXT Pty Ltd | 4,514,468 | 10.12% |
| Elk River Holdings Pty Ltd | 2,492,142 | 5.58% |
| 34th Avenue Pty Ltd |
2,215,237 | 4.96% |
| Christopher John Burns | 2,215,237 | 4.96% |
| Mark Sullivan |
1,661,428 | 3.72% |
| Warwick Tong | 1,661,428 | 3.72% |
| Cancer Research Technology Limited | 1,360,524 | 3.05% |
| Merrill Lynch (Australia) Nominees Pty Limited | 1,160,610 | 2.60% |
| Margaret Frame | 923,016 | 2.07% |
| Neil Oliver Carragher | 553,809 | 1.24% |
| Mr Ian Heraud + Mrs Fiona Heraud |
500,000 | 1.12% |
| Ms Caitlin Collins | 500,000 | 1.12% |
| National Nominees Limited |
500,000 | 1.12% |
| Symington Pty Ltd | 400,000 | 0.90% |
| Yelwac Pty Ltd |
400,000 | 0.90% |
| Mrs Patricia Watkins + Mr John Phibbs + Mr Graeme Halse | 377,750 | 0.85% |
| Probe International Inc | 369,269 | 0.83% |
| Mr Andrew Podolak | 360,000 | 0.81% |
| Chep LI LLC | 352,532 | 0.79% |
| All other shareholders | 35.29 % | |
The Top 20 Shareholders of ATX hold 64.71% of shares on issue.
ATX Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
ATX Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|---|---|
| 2019 | $0.097 | 28 June |
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Development of these drug candidates for potential use in multiple indications including immuno-oncology and chronic fibrosis.
Incorporated: --
Level 29, 55 Collins St
Melbourne VIC 3000
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.